"Pharma is one of the few sectors where mature franchises, regulatory moats, and predictable free cash flow fund decades of uninterrupted payouts. Patent cliffs and pricing pressure compress multiples, which is why several big-cap drugmakers now trade with yields well above the S&P 500 average."
"AstraZeneca is a UK-domiciled global drugmaker with leadership in oncology, rare disease, and biopharmaceuticals. Q1 2026 revenue grew 13% to $15.29B, with oncology up 20% on Tagrisso, Imfinzi, and Enhertu."
"Johnson & Johnson is a Dividend King with 64 consecutive years of increases, most recently a 3.1% raise to $1.34 per quarter payable June 9, 2026. Innovative Medicine grew 11.2% in Q1 led by DARZALEX and TREMFYA."
"Merck anchors the portfolio with KEYTRUDA, which generated $8.03B in Q1 (up 12%), alongside fast-growing WINREVAIR and a recovering Animal Health segment. The quarterly payout was raised to $0.85, an annualized $3.40."
High-yield equities, particularly in the pharmaceutical sector, offer consistent dividend income regardless of market fluctuations. These investments provide immediate cash flow, allowing for easy redeployment or spending. Companies like AstraZeneca, Johnson & Johnson, and Merck are highlighted for their strong revenue growth and reliable payouts. AstraZeneca plans to increase its dividend significantly, while Johnson & Johnson maintains a long history of dividend increases. Merck's strong product performance supports its dividend growth, making these stocks attractive for income-focused investors.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]